Form D · Biotechnology
IMMvention Therapeutix, Inc.
Durham, NC · CIK 0001837999
Offering snapshot reported Jan 10, 2023 · SEC filing
- Reported sold
- $2M Offering amount: $4M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 23, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2023 | Initial | $1,999,999 | No comparison | 4 | SEC filing |
| Nov 19, 2021 | Amendment | $6,899,999 | $2,997,497vs Dec 28, 2020 | 5 | SEC filing |
| Dec 28, 2020 | Initial | $3,902,502 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-470125
Source: Form D, filed Jan 10, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Matthew Cohen | Director |
| Anil Goyal | Director, Executive |
| Lev Osherovich | Director |
| Benjamin Scruggs | Director |
| Marilyn Thompson | Executive |
| Jenny Ting | Director |
| Mark Vellaca | Director |
| Mark Velleca | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
9 Laboratory Drive Suite 264
Durham, NC, 27709
Durham, NC, 27709